Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy constant epsilon P1 (IGHEP1) is classified as a pseudogene in the human genome and does not encode a functional protein. IGHEP1 shares sequence homology with IGHE, the gene coding for the constant region of the epsilon heavy chain of immunoglobulin E (IgE), but lacks coding potential and is not known to have a biological role in immune function or disease. There are no known drugs targeting this pseudogene, nor is it used as a biomarker or considered therapeutically relevant. Its status as a pseudogene distinguishes it from the protein-coding IGHE gene, which mediates IgE antibody responses central to allergic diseases and parasitic defense[4][7]. - IGHEP1: pseudogene, not a functional receptor, enzyme, or other therapeutic target[4][7]. - No biological processes, drug interactions, or clinical relevance have been attributed to IGHEP1 in current biomedical resources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy constant epsilon P1 (IGHEP1).